AstraZeneca plc is a British multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2012 prescription drug sales and has operations in over 100 countries.AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Sweden-based Astra AB and the UK-based Zeneca Group . It has made numerous corporate acquisitions, including of Cambridge Antibody Technology , MedImmune , and Spirogen .AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £54.8 billion as of 1 August 2014, the sixth largest of any company with a primary listing on the London Stock Exchange. It has secondary listings on the New York Stock Exchange and the OMX exchange. Wikipedia.
Astrazeneca and Array BioPharma | Date: 2016-11-10
The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Astrazeneca | Date: 2016-10-12
The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
Astrazeneca and MedImmune Ltd | Date: 2016-07-28
Bayer Pharma Aktiengesellschaft and Astrazeneca | Date: 2016-12-02
A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
Astrazeneca | Date: 2016-09-16
The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R^(1), R^(2), R^(3), R^(4 )and R^(5 )have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
Astrazeneca | Date: 2016-09-22
Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein
Astrazeneca | Date: 2016-11-08
The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
Astrazeneca | Date: 2016-11-15
The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z^(1), Z^(2), R^(1), R^(4), R^(5 )and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.97M | Year: 2017
MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combined with drug delivery, cellular biology and experimental medicine. This project represents a concerted effort to make use of a basic and quantitative understanding of chemical interactions to develop and deliver oligonucleotide molecules of utility for therapy. Our chemical biology approach to this field is ambitious in its breadth and represents a unqiues opportunity to educate young scientists across sectorial and disciplinary barriers. Training will naturally encompass a wide range of skills, requiring a joint effort of chemists and biologists to introduce young researchers in a structured way to and array of research methodologies that no single research grouping could provide. The incorporation of early-stage and later stag ebiotechnology enterprises ensures that commercialisation of methodologies as well as the drug development process is covered in this ITN. We hope that MMBio will train scientists able to understand both the biological problem and the chemistry that holds the possible solution and develop original experimental approaches to stimulate European academic and commercial success in this area.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.95M | Year: 2016
Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Metabolism and Excretion studies carried out on larger series of drug candidates at an earlier stage of the DDD timeline and evaluation of drug efficacy through better assessment of pharmacokinetic/pharmacodynamic relationships, target engagement and receptor occupancy are critically important approaches for de-risking drug innovation since they facilitate early identification of the candidates that display the best in vivo profile. When successfully implemented, this strategy can accelerate the discovery of new therapeutic solutions to existing and emerging diseases, and enhance European pharmaceutical innovation. For implementation, large sets of isotopically-labeled molecules are required and consequently, a huge revival of labeling techniques is urgently needed. Another crucial issue is the scarcity of expert radiochemists in Europe and the lack of first class training programs in this inter-disciplinary field merging chemistry, radiochemistry and medicinal chemistry. The aims of ISOTOPICS are: i) to train the next generation of European chemists with expertise in isotopic labeling and advanced medicinal chemistry through a first-class taught and research training program combined with a highly interactive secondments plan; ii) to develop innovative and general isotopic labeling chemistry and radiochemistry to streamline the synthesis of labeled small-molecule drugs and biologics; iii) to work closely with the European pharmaceutical industry to apply the new labeling methods to drugs currently in development in order to provide solutions to the most pressing problems in drug innovation. This highly interdisciplinary project is expected to have a profound beneficial impact on drug innovation in Europe by providing novel efficient techniques and new experts in the fields of labeling and medicinal chemistries.